Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | F3 | P13726 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604969 | 0.73 | CHRNB2 (0.77) | L3MBTL1HTTALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL7605547 | 0.73 | F3 (0.53) | HTTF3 | |
| SCHEMBL7611713 | 0.73 | L3MBTL1 (0.63) | L3MBTL1HTTALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL7048961 | 0.71 | CHRNB2 (0.71) | L3MBTL1HTTALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL7607183 | 0.70 | HSD17B10 (0.66) | ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7611573 | 0.70 | CHRNB2 (0.69) | L3MBTL1HTTALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL7611716 | 0.70 | CHRNB2 (0.61) | L3MBTL1HTTALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL7610932 | 0.69 | CHRNB2 (0.60) | L3MBTL1HTTALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL7611559 | 0.69 | CHRNB2 (0.68) | L3MBTL1HTTALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL21446827 | 0.69 | CHRNB2 (0.68) | L3MBTL1HTTALDH1A1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | MTTP, CETP, FABP1 | L3MBTL1 3333/4885HTT 3107/4885ALDH1A1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.